Recombinant Mycobacterium bovis BCG

被引：73

作者：

Bastos, Reginaldo G. ^{[2
]}

Borsuk, Sibele ^{[1
]}

Seixas, Fabiana K. ^{[1
]}

Dellagostin, Odir A. ^{[1
]}

机构：

[1] Univ Fed Pelotas, Ctr Biotecnol, Mol Biol Lab, BR-96010900 Pelotas, RS, Brazil

[2] Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA

来源：

VACCINE | 2009年 / 27卷 / 47期

关键词：

Mycobacterium bovis BCG; Recombinant BCG; Heterologous expression; Immunomodulator; BACILLUS-CALMETTE-GUERIN; HUMAN-IMMUNODEFICIENCY-VIRUS; SURFACE PROTEIN-A; CELLULAR IMMUNE-RESPONSES; EXPRESSING INTERFERON-GAMMA; RESPIRATORY-SYNDROME-VIRUS; GLUTATHIONE-S-TRANSFERASE; CYTOTOXIC T-LYMPHOCYTES; LYME-DISEASE VACCINE; PROTECTIVE IMMUNITY;

D O I：

10.1016/j.vaccine.2009.08.044

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The Bacillus Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis that has been broadly used as a vaccine against human tuberculosis. This live bacterial vaccine is able to establish a persistent infection and induces both cellular and humoral immune responses. The development of mycobacterial genetic systems to express foreign antigens and the adjuvanticity of BCG are the basis of the potential use of this attenuated mycobacterium as a recombinant vaccine. Over the years, a range of strategies has been developed to allow controlled and stable expression of viral, bacterial and parasite antigens in BCG. Herein, we review the strategies developed to express heterologous antigens in BCG and the immune response elicited by recombinant BCG constructs. In addition, the use of recombinant BCG as an immunomodulator and future perspectives of BCG as a recombinant vaccine vector are discussed. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：6495 / 6503

页数：9

共 50 条

[21] Survival of Mycobacterium tuberculosis and Mycobacterium bovis BCG in lysosomes in vivo
Sundaramurthy, Varadharajan
Korf, Hannelie
Singla, Ashima
Scherr, Nicole
Nguyen, Liem
Ferrari, Giorgio
Landmann, Regine
Huygen, Kris
Pieters, Jean
MICROBES AND INFECTION, 2017, 19 (11) : 515 - 526
[22] IDENTIFICATION DE MYCOBACTERIUM BOVIS BCG ET MYCOBACTERIUM MICROTI
BOISVERT, H
ANNALES DE L INSTITUT PASTEUR, 1966, 111 (02): : 180 - +
[23] Mycobacterium bovis BCG binds factor H
Aziz, M. Abdul
Carroll, M.
Sim, R. B.
Sim, E.
IMMUNOLOGY, 2011, 135 : 86 - 86
[24] Auxotrophic Mycobacterium bovis BCG: Updates and Perspectives
Dellagostin, Odir Antonio
Borsuk, Sibele
Oliveira, Thais Larre
Seixas, Fabiana Kommling
VACCINES, 2022, 10 (05)
[25] Mycobacterium bovis BCG in metastatic melanoma therapy
Martha Lucia Ruiz Benitez
Camila Bonnemann Bender
Thaís Larré Oliveira
Kyle M. Schachtschneider
Tiago Collares
Fabiana Kömmling Seixas
Applied Microbiology and Biotechnology, 2019, 103 : 7903 - 7916
[26] Immunosorbents for the preparation of Mycobacterium bovis BCG antigen
Krejcikova, S
Benes, MJ
Wisingerova, E
Turkova, J
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1996, 61 (12) : 1823 - 1830
[27] Mycobacterium bovis BCG in metastatic melanoma therapy
Ruiz Benitez, Martha Lucia
Bender, Camila Bonnemann
Oliveira, Thais Larre
Schachtschneider, Kyle M.
Collares, Tiago
Seixas, Fabiana Koemmling
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2019, 103 (19) : 7903 - 7916
[28] Recombinant AhpC antigen from Mycobacterium bovis boosts BCG-primed immunity in mice
Duzenli, Ozgun Firat
Okay, Sezer
Kazkayasi, Inci
Oner, Ayse Filiz
TURKISH JOURNAL OF BIOLOGY, 2022, 46 (01) : 95 - +
[29] Immune response induced by recombinant Mycobacterium bovis BCG producing the cholera toxin B subunit
Biet, F
Kremer, L
Wolowczuk, I
Delacre, M
Locht, C
INFECTION AND IMMUNITY, 2003, 71 (05) : 2933 - 2937
[30] Genetic control of antibody responses induced by recombinant Mycobacterium bovis BCG expressing a foreign antigen
Lagranderie, M
LoMan, R
Deriaud, E
Gicquel, B
Gheorghiu, M
LeClerc, C
INFECTION AND IMMUNITY, 1997, 65 (08) : 3057 - 3064

← 1 2 3 4 5 →